Glenmark to Launch Micafungin Injection in US From SeptemberG

Glenmark Pharmaceuticals Inc. USA, a unit of Glenmark Pharmaceuticals Ltd., said it will launch Micafungin injection in the US market from September.

The antifungal drug will be available in 50 mg and 100 mg vials and is the bioequivalent of Mycamine injection, owned by Astellas Pharma US Inc.

Quoting IQVIA data, Glenmark said sales of Micafungin injection in the US stood at $61 million for the 12 months ended June. The company said the launch will strengthen its institutional channel product portfolio.